Clinical Trial Update: A Safety, Efficacy and Biomarker Study of JNJ-42847922 in Participants With Major Depressive Disorder [Phase 1]

View source ↗

Summary

This update covers a Phase 1 safety, efficacy and biomarker study of JNJ-42847922 in people with major depressive disorder, which has completed the trial.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• JNJ-42847922

Snippet

Sponsor: Janssen-Cilag International NV | Conditions: Major Depressive Disorder | Phase 1 | Status: COMPLETED